Lottery.com Expands Its Global Footprint in Live Entertainment with $10M Acquisition of Concerts.com and TicketStub.com
Acquiring a majority stake in DVI represents a $10 million transaction, comprised of a strategic blend of cash, secured debt, and equity issued at up to $3.00 per share — further validating the strength of the Lottery.com and Sports.com platform.
'While Concerts.com and Sports.com are hallmark media brands, we intend to make TicketStub.com the trusted ticketing site for fans of all live entertainment. Concerts.com is the perfect third vertical for our business. It will become the ticketing engine for Sports.com — giving us a unified commerce and content strategy around everything from sports to festivals to immersive experiences.'
This strategic investment will form the third foundational pillar of Lottery.com's expanding platform — standing alongside Sports.com and Lottery.com as part of a vertically integrated, multi-channel entertainment business. Together, these brands will create the concrete base of a next-generation ecosystem designed to unify content, commerce, and live experiences under a single global strategy. Concerts.com and TicketStub.com are live, operational, and built for scale — delivering real value and revenue potential from day one. The platforms feature:
FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (NASDAQ: LTRY, LTRYW), a leading technology company transforming the intersection of gaming, sports, and entertainment, today announced that it has signed a Letter of Intent ('LOI') to acquire a majority stake in DotCom Ventures Inc., a Nevada corporation ('DVI'), together with the premium domain assets Concerts.com and TicketStub.com, in a transaction valued at $10 million.
Story Continues
'Deals like this, which include stock at $3 per share, reinforce the belief in the value we're building with Lottery.com, Sports.com and now, Concerts.com,' McGahan added. 'This isn't just an acquisition; it's a commitment to a five-year vision, and a statement to the market that we are serious about scaling globally with premium digital assets.'
A Long-Term Partnership with a Shared Vision
'Our vision of providing fans with the information and access they need to discover the live events they want can now be realized on a global scale through Concerts.com and Sports.com,' said Patrick Ogle, CEO and founder of DVI. 'DVI looked at several other partners over the last year. Ultimately, we knew that these assets belong together, and fans deserve reliable access to a live entertainment platform they can trust. With the backing of Lottery.com and the infrastructure behind Sports.com, we're building more than a platform — we're creating a new standard for how fans connect to live experiences.'
Ogle is an entrepreneurial lawyer and digital strategist with more than two decades of experience spanning media, entertainment, and athlete representation. From his early days as an intern at Jerry Bruckheimer Films and Television and Network Music Group, to 20+ years managing the business and legal affairs of athletes and entertainers, Ogle has built a career at the intersection of entertainment and infrastructure. He is a former 15-year member of The Recording Academy, and an active voting member of the Country Music Association.
'Patrick brings more than just the domain — he brings a deep understanding of what this vision can become,' said Gregory Potts, Chief Operating Officer of Lottery.com. 'Entering into this LOI is a clear vote of confidence — not just in the value of the brands, but in our collective ability to execute together over the next five years. This is an exciting culmination of a relationship that began in 2023, appropriately, at the Pilgrimage Music Festival in Franklin, TN.'
The final transaction will include the assumption of secured notes and a multi-stage stock issuance structure, reflecting alignment and long-term commitment from all parties.
Powering the Future of Live Entertainment
Concerts.com is being designed not simply as a ticketing platform, but as a fully integrated live events engine. It will serve as the primary processor of access and fan engagement, tying directly into Sports.com's fast-growing live streaming infrastructure.
The investment in DVI will include TicketStub.com, which will operate in parallel as a brand focused on alternative entertainment verticals, including festivals, comedy, esports, and niche lifestyle events. This dual-brand strategy allows for both mainstream and genre-specific ticketing models under the broader Concerts.com umbrella.
As part of the short and mid-term roadmap:
The brand will integrate with live streaming functionality and real-time access models across all Lottery.com and Sports.com verticals
Sports.com's ambassador network will amplify events across social platforms
Concerts.com will power bundled experiences combining tickets + content + streaming
Deliver to consumers crossover activations between sports, music, charitable gaming and culture
Sports.com Studios will create proprietary content for Concerts.com
Domain Portfolio Strength
With the addition of Concerts.com and TicketStub.com, Lottery.com will hold what it believes to be one of the strongest domain portfolios in the world. With Lottery.com, Sports.com, and now Concerts.com, the company stands alone in its control of three world-class, category-defining digital assets.
'Very few — if any — companies can claim three domains of this caliber,' said McGahan. 'And we believe the combination of Lottery.com, Sports.com, and Concerts.com is without peer in the global digital entertainment space. These assets will anchor the next decade of innovation across content, commerce, and live experiences.'
McGahan went on to say that with the addition of these assets, he believes Lottery.com is arguably one of the most exciting investment opportunities on the exchange today.
'This is a unique opportunity to invest in a company with premium global assets and a bold vision for the future of entertainment, gaming and live events.'
About Lottery.com
The Lottery.com Inc. (NASDAQ: LTRY, LTRYW) family of brands — including Sports.com, Concerts.com, and TicketStub.com, is a unified ecosystem that integrates gaming, entertainment, and sports.
Important Notice Regarding Forward-Looking Statements
This press release contains statements that constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words 'could,' 'should,' 'will,' 'may,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'project,' 'initiatives,' 'continue,' the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company's internal accounting controls, additional examination of the preliminary conclusions of such review, the Company's ability to secure additional capital resources, the Company's ability to continue as a going concern, the Company's ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company's ability to regain compliance with the Bid Price Requirement, the Company's ability to regain compliance with Nasdaq Listing Rules, the Company's ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading 'Risk Factors' in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.
This press release was published by a CLEAR® Verified individual.
CONTACT: For more information, please visit www.lottery.com or contact our media relations team at press@lottery.com.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
25 minutes ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio